

**ASX Announcement
10 June 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)**

Optiscan Reveals InSpecta™ Device for Veterinary Medicine

This innovative imaging device, designed to enhance diagnostics and treatment for the veterinary market, including its highly lucrative companion animal segment, is another key deliverable in Optiscan's stated growth strategy.

Highlights

- Optiscan reveals InSpecta™, a novel microscopic imaging device specifically designed for veterinary medicine.
- InSpecta™ expands Optiscan's product portfolio and its associated addressable market into the highly lucrative, high growth global veterinary medicine segment.
- InSpecta™ is designed to enhance diagnostics and treatment for companion animals by delivering real-time, non-invasive imaging.
- InSpecta™ is tangible evidence that Optiscan's stated plans to expand its product range into the veterinary medicine market segment is being realised.
- The device will be showcased at the prestigious American College of Veterinary Internal Medicine (ACVIM) conference in Louisville, Kentucky on 19-21 June 2025.
- The InSpecta™ device will be tested at Optiscan's veterinary medicine partner institution, the University of Minnesota College of Veterinary Medicine, to help support regulatory submissions.

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company') is pleased to announce the reveal of InSpecta™, a novel microscopic imaging device designed specifically for the veterinary medicine market segment. The device will be showcased at the prestigious American College of Veterinary Internal Medicine (ACVIM) conference in Louisville, Kentucky on 19-21 June 2025.

InSpecta™ materially expands Optiscan's addressable market

The InSpecta™ device reveal shows Optiscan is delivering on its stated commitment to, as part of its broader growth strategy, gradually expand the Company's product portfolio. Built on Optiscan's proprietary technology, this innovative device is designed specifically for animals, offering a compact, durable and portable device, which has a small footprint and is ruggedized allowing use across multiple settings from an in-office environment to fieldwork in rural surroundings. It will enable rapid insights that enhance diagnostics and treatment across the full veterinary medicine workflow.

The reveal of InSpecta™ means Optiscan now has in place a device for use in the highly lucrative veterinary medicine market segment. It offers real-time, non-invasive imaging for a broad range of animals that is far superior to the way medical conditions are currently diagnosed and treated by veterinary medicine

professionals.



The InSpecta™ device gives Optiscan the means to fill an existing crucial gap in veterinary medicine which impacts millions of animals around the world. In the process, the device significantly broadens the addressable market for Optiscan's overall product suite to now also include the highly lucrative veterinary market. The US veterinary market alone was valued at approximately US \$11.92 billion in 2022, and is projected to grow at a strong compound annual growth rate

(CAGR) of 8.7% through 2030.¹ With around 76 million dogs and 60 million cats in US households, the demand for veterinary services—especially for treating complex conditions like cancer—is already huge and is set to grow further over coming years.

While Optiscan's initial focus will be demonstrating the ability of the InSpecta™ device to enhance diagnostics and treatment for companion animals, the Company anticipates that the device will also offer immense potential across all categories of veterinary medicine. The equine veterinary sector, for example, stands to benefit from real-time, non-invasive imaging that improves surgical precision and diagnostic accuracy. Beyond horses, this cutting-edge technology enables veterinary professionals to deliver faster, more effective care across a wide range of species. By integrating Optiscan's advanced imaging solutions, veterinary practices can enhance patient outcomes, streamline treatment approaches, and elevate the overall standard of care in veterinary medicine.

InSpecta™ testing at University of Minnesota College of Veterinary Medicine

The InSpecta™ device will be tested at Optiscan's veterinary medicine partner institution, the University of Minnesota College of Veterinary Medicine (see ASX announcement dated 18 November 2024). This test work will allow the Company to gather data on clinical utility and to support regulatory submissions. Optiscan will update the market on outcomes from this testing process in due course.

Optiscan CEO and Managing Director, Dr Camile Farah, said: "We are thrilled to reveal the InSpecta™ device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta™ is based on the Company's life sciences imaging platform, ViewnVivo®, and offers veterinarians an easy to use, portable and robust imaging device which is purposefully designed for their particular needs. It can be used for both in vivo and ex vivo applications, broadening the appeal and applicability of the technology to the

widest possible audience in veterinary medicine. The product incorporates feedback from our interactions with veterinary medicine professionals over the course of its design stage. These two-way discussions saw us receive overwhelmingly positive responses about our planned introduction of this technology into the veterinary sector.”

Dr Farah added: “The veterinary device market is regulated in a different manner to the human medical device industry, which opens the way for our InSpecta™ device to gain earlier market entry into what is, for our Company, a new lucrative vertical. Optiscan will spend the rest of this year refining the regulatory and commercial plans for our InSpecta™ product. This work will see our team continue to engage with the veterinary medicine industry exploring market opportunities, collaborations and partnerships that position InSpecta™ as the device of choice for microscopic veterinary imaging.”

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

¹ <https://www.grandviewresearch.com/industry-analysis/us-veterinarians-market>